The renoprotective effect of angiotensin receptor blockers (ARB) among Asian population:evidence from clinical studies

The renoprotective effect of angiotensin receptor blockers (ARB) among Asian population:evidence from clinical studies

碩士 === 高雄醫學大學 === 藥學研究所碩士在職專班 === 102 === Abstract Background： Angiotensin receptor blockers (ARB) has been demonstrated as an effective treatment for hypertension and other cardiovascular (CV) disorders. The renoprotective effect could be a potential benefit of ARB. As potential ethnic difference c...

Full description

Bibliographic Details
Main Authors:	Hui-Chen Yang, 楊卉蓁
Other Authors:	Shun-Jin Lin
Format:	Others
Language:	zh-TW
Published:	2014
Online Access:	http://ndltd.ncl.edu.tw/handle/81567930449448769840

Similar Items

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
by: John Matsoukas, et al.
Published: (2021-01-01)

Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers
by: Pauline A Swift, et al.
Published: (2001-09-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
by: Duprez D, et al.
Published: (2011-11-01)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
by: Wenjun Wang, et al.
Published: (2021-01-01)

The Renoprotective Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Chronic Kidney Disease
by: Wen-Chuan Lin, et al.
Published: (2002)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2016)

ANALYSIS OF CHANGE IN NT-proBNP AFTER ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY IN PATIENT WITH HEART FAILURE
by: Intan Kusuma Dewi, et al.
Published: (2017-08-01)

Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease
by: Ping-Min Chen, et al.
Published: (2014-04-01)

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
by: Georg Nickenig, et al.
Published: (2006-03-01)

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
by: Georg Nickenig, et al.
Published: (2006-03-01)

Renin-Angiotensin System Blockers and Renal Functional Reserve. Is There a Limit of Renoprotection?
by: D.D. Ivanov
Published: (2015-10-01)

Controversy of angiotensin receptor blockers (ARBs) and angiotensin converting enzymeinhibitors (ACEIs) prescription for hypertension patients in coronavirus disease 2019 (COVID-19) pandemic
by: Yuliana Yuliana
Published: (2020-05-01)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
by: Rawan ElAbd, et al.
Published: (2021-03-01)

Comparison of Angiotensin-Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) for Heart Failure Treatment in Congenital Heart Diseases with Left-to-Right Shunt
by: Alit Utamayasa, et al.
Published: (2020-03-01)

Reply to comment on “Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease”
by: Ping-Min Chen
Published: (2015-01-01)

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin–Angiotensin System
by: Akira Nishiyama, et al.
Published: (2010-01-01)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
by: Dan-Dan Qiu, et al.
Published: (2018-01-01)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
by: Paranjpe R, et al.
Published: (2020-10-01)

Renoprotective effect of calcium channel blockers
by: Dimković Nada, et al.
Published: (2009-01-01)

BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL
by: I. T. Murkamilov, et al.
Published: (2017-07-01)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
by: Kenichiro Kinouchi, et al.
Published: (2011-01-01)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
by: Eiichiro Tanaka, et al.
Published: (2013-09-01)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
by: Gabriel Augusto Pires de Souza, et al.
Published: (2021-06-01)

Angiotensin receptor blocker selectivity at the AT- and AT-receptors: conceptual and clinical effects
by: Thomas Unger, et al.
Published: (2000-06-01)

Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy
by: Martin P Bedigian
Published: (2000-06-01)

A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery
by: Hollmann, Caryl
Published: (2020)

Improving the prognosis of diabetic patients: Evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy
by: Martin P Bedigian
Published: (2000-06-01)

Clinical pharmacology of angiotensin II receptor blockers: valsartan
by: M. V. Leonova
Published: (2014-12-01)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
by: Hyun Woong Lee
Published: (2014-12-01)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
by: Rong-Shuang Huang, et al.
Published: (2016-01-01)

Angiotensin receptor blockers in heart failure
by: Jan Östergren, et al.
Published: (2003-09-01)

Comparative assessment of angiotensin receptor blockers in different clinical settings
by: Paolo Verdecchia, et al.
Published: (2009-11-01)

Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the future
by: Michael Weber
Published: (2001-06-01)

Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future
by: Michael Weber
Published: (2001-06-01)

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers
by: Neil Poulter, et al.
Published: (2006-06-01)

Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: conceptual and clinical effects
by: Thomas Unger, et al.
Published: (2000-06-01)

Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure
by: Jay N Cohn
Published: (2003-09-01)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
by: Graham J. Moore, et al.
Published: (2021-07-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: M L Maksimov, et al.
Published: (2017-03-01)